Syndecan-1, also known as CD138, is one of the four transmembrane glycoproteins in the Syndecan family of proteoglycans. This protein is expressed in early precursor B cells and re-expressed during differentiation into plasma cells. Members of the Syndecan family function as coreceptors on the cell surface, regulating biological processes such as cell adhesion, migration, proliferation, and differentiation. As a specific marker for plasma cells, CD138 detection is crucial for diagnosing related diseases. FITC-labeled Syndecan-1/CD138 His-tagged protein can be used to quantitatively measure CD138 protein expression levels and binding activity, providing a technical tool for immunohistochemical research.
In bone marrow biopsy specimens, CD138 is a key marker for identifying and characterizing plasma cells. Both normal and neoplastic plasma cells strongly express CD138 protein. Immunohistochemical staining can assess the quantity, distribution, and morphology of plasma cells in the bone marrow. In plasma cell neoplasms such as multiple myeloma, CD138-positive plasma cells exhibit diffuse or clustered distribution, aiding differential diagnosis. CD138 staining also helps evaluate the extent and degree of involvement in plasma cell neoplasms. In reactive plasmacytosis, CD138-positive plasma cells typically show polyclonal distribution, distinguishing them from neoplastic plasma cells. FITC-labeled Syndecan-1/CD138 His-tagged protein can standardize immunohistochemical detection protocols, improving result reproducibility.
In mature B-cell neoplasms, CD138 positivity suggests plasma cell or post-follicular differentiation. Certain B-cell lymphomas may differentiate toward plasma cells, showing CD138 expression. In lymphoplasmacytic lymphoma, some tumor cells may express CD138. In diffuse large B-cell lymphoma, CD138 expression is observed in subtypes with plasma cell differentiation. In mucosa-associated lymphoid tissue (MALT) lymphoma, areas of plasma cell differentiation may show CD138 positivity. CD138 staining helps determine the differentiation stage of B-cell neoplasms, supporting pathological diagnosis. However, CD138 negativity does not entirely exclude plasma cell differentiation and requires evaluation with other markers.
CD138 may aid in differentiating mesothelioma from adenocarcinoma. Mesothelioma is typically CD138-negative, while approximately 55% of adenocarcinomas are CD138-positive. In pleural and peritoneal biopsy specimens, CD138 staining can serve as an auxiliary diagnostic marker. However, relying solely on CD138 has limitations, requiring combination with other markers such as calretinin, cytokeratin 5/6, carcinoembryonic antigen, and MOC-31 for comprehensive evaluation. Some adenocarcinomas may be CD138-negative, while rare mesotheliomas may weakly express CD138, necessitating appropriate antibody panels for accurate differentiation. FITC-labeled Syndecan-1/CD138 His-tagged protein can standardize staining protocols, enhancing diagnostic accuracy.
Some non-lymphohematopoietic tumors with plasmacytoid morphology may exhibit CD138 positivity. These include squamous cell carcinoma, myoepithelioma, medullary thyroid carcinoma, and melanoma. In these tumors, CD138 expression may relate to plasmacytoid morphology but does not indicate true plasma cell differentiation. Therefore, when diagnosing tumors with plasmacytoid features, CD138 positivity alone should not lead to a plasma cell neoplasm diagnosis. Appropriate antibody panels are essential for differentiation, including markers such as cytokeratins, S-100 protein, calcitonin, and HMB45. CD138 staining should be used as part of a combined marker approach.
In CD138 immunohistochemical detection, positive staining localizes to the cell membrane and cytoplasm. Optimal antigen retrieval conditions are crucial for ideal staining results. CD138 is sensitive to tissue fixation and processing; overfixation may cause antigen loss, while underfixation may compromise morphology. Appropriate antigen retrieval solution concentration and duration ensure adequate antigen exposure. Control tissue setup is vital for interpretation, including positive and negative controls. During interpretation, endogenous biotin may cause false-positive staining, which can be mitigated using biotin blocking systems. FITC-labeled Syndecan-1/CD138 His-tagged protein serves as a positive control to validate staining system reliability.
As a specific plasma cell marker, CD138 holds significant value in hematopathological diagnosis. FITC-labeled Syndecan-1/CD138 His-tagged protein provides a sensitive and efficient detection tool for studying CD138 protein expression, distribution, and interactions, applicable to immunohistochemical method optimization, antibody screening, and quality control. Future research will further explore CD138 expression profiles in normal and diseased tissues, develop more sensitive and specific detection methods, and evaluate CD138's role in novel plasma cell neoplasm treatment strategies. As understanding of CD138's biological functions deepens, its applications in pathological diagnosis will continue to expand.
Nanjing UA-Bio Technology Co., Ltd. (UA-Bio) has independently developed "FITC-Labeled Syndecan-1/CD138 His Tag Protein, Human" (Catalog No.: UA011283), a high-performance fluorescent-labeled probe specifically designed for research on plasma cell disorders such as multiple myeloma and targeted drug development. This protein is human-derived Syndecan-1/CD138 with His tag and FITC labeling, capable of efficiently binding anti-CD138 antibodies or affinity ligands. It provides a stable and reliable standardized tool for CAR-T cell therapy evaluation, antibody drug screening, and plasma cell disorder marker research.
| Core Product Advantages | Detailed Parameters / Functional Description | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| High Purity and Intact Bioactivity | The product utilizes an advanced eukaryotic expression system and highly standardized purification processes, validated through multi-dimensional quality control to ensure >95% purity and correct native conformation (retaining complete glycosylation). The FITC labeling process is optimized to maintain high labeling efficiency while preserving the protein's high-affinity binding to antibodies, accurately mimicking CD138's antigenic properties on multiple myeloma cell surfaces under physiological conditions.--
|
Nanjing UA-Bio Technology Co., Ltd. is committed to providing cutting-edge, high-quality core reagents and tools for immunology, cell therapy, and innovative drug development. For detailed technical parameters, validation data, or application inquiries regarding "FITC-Labeled Syndecan-1/CD138 His Tag Protein, Human" (Catalog No.: UA011283), please feel free to contact us.
